December 14, 2020

PPMD Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technology

Parent Project Muscular Dystrophy is excited to announce a $1 million programmatic investment in Satellos Bioscience Inc. (Satellos) to support the development of a new regenerative medicine for the therapeutic treatment of Duchenne. Duchenne is…

Learn More

December 12, 2020

WATCH: COVID-19 Vaccination & Duchenne: What You Need To Know (Webinar Recording)

We all have spent the last several months doing our best to keep ourselves and our families safe, while adjusting to this new virtual world. PPMD recognizes this has been nothing short of challenging, and…

Learn More

December 11, 2020

Have Your Gift Matched to Unlock Data and Unleash Breakthroughs

This time of year, we are all looking for the perfect gift for our loved ones, but one size doesn’t fit all. This reminds me of Duchenne, where one size doesn’t fit all either. While…

Learn More

December 10, 2020

The Duchenne Registry Celebrates One Year of Data Collection in our Smartphone App!

This year has been one for the record books for many reasons, but here at PPMD we are excited to celebrate one year of data collection in The Duchenne Registry’s new smartphone app platform! Our…

Learn More

December 9, 2020

What exactly is a “Duchenne Protein Map”?

One thing we all know about Duchenne is that no matter when you or your child was diagnosed, some days we wake up and find ourselves feeling like there is still so much we need…

Learn More

December 7, 2020

Support PPMD to Unleash Breakthroughs

It is hard to believe that we are here — in the throes of the “magic” of the holiday season. 2020 has not felt much like magic. Instead, a roller coaster of unpredictability and worry. But…

Learn More

December 7, 2020

Sarepta Announces Positive Clinical Results from MOMENTUM Phase 2 Clinical Trial of SRP-5051

Sarepta has announced positive results from the ongoing MOMENTUM study of SRP-5051, its next-generation treatment for individuals with Duchenne who are amenable to exon 51 skipping. This is the first clinical data from SRP-5051, an…

Learn More

December 3, 2020

WATCH: SRP-9001 Gene Therapy Path Forward (Webinar Recording)

Parent Project Muscular Dystrophy and Sarepta Therapeutics hosted a webinar on November 24, 2020 for a discussion about the SRP-9001 gene therapy development program. If you missed the live event, the recording can be found…

Learn More

November 25, 2020

I’m thankful for what we have in each other.

This year. This Thanksgiving. How did we get here? This year has tested our will, our resilience, and our courage. I still have a turkey in the oven and dessert in the fridge, but my…

Learn More

November 25, 2020

Antisense Therapeutics: Introduction to the Duchenne Community

PPMD is thrilled to welcome Antisense Therapeutics to the Duchenne community. Antisense is developing a new potential therapy, ATL1102, using an antisense oligonucleotide (ASO) inhibitor aimed at treating muscle inflammation and associated muscle wasting. Although…

Learn More